EntelMed’s strategy is to accelerate the drug discovery process by making it easier to identify promising compounds using blockchain, AI, and Quantum Computing.
Our initial objective involves an unprecedented volume of data, at least 10 million physical compounds, a minimum of 200 million activity data points collected in dose-response analyses, and more than a billion assay activity data points.
The value of pharmaceutical data has not been fully realized. EntelMed’s strategic objective is to develop technology to start to unlock that value. $2 Billion to Bring a Drug to Market
It takes 13 years and an average of almost $2 billion to bring a drug to market. It would benefit everyone, especially patients if we could become more efficient. The pharmaceutical industry has long been searching for a way to pool knowledge without compromising the confidentiality of their data.
To decrease the financial cost and chances of failure, pharmaceutical companies are shifting towards AI. We believe AI will revolutionize the pharmaceutical and medical sectors. Various pharmaceutical companies have made and continue investing in AI and have collaborated with AI companies to develop essential healthcare tools.